NFKB1 and non-Hodgkin lymphoma: According to Jazirehi et al. (2005), Jazirehi et al. (2005) and Bonavida (2007), Jazirehi and Bonavida (2005), treating Non-Hodgkin’s lymphoma (NHL) B cell lines with Rituximab inhibits NF-κB’s signaling pathways by up-regulating RKIP and Raf-1 kinase inhibitors.